Due to health issues, this site is no longer maintained and will be shut down shortly. |
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:MDNA.
$0.54 +0.00 (0.32%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.